🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Mariano Severgnini

Dana-Farber Cancer Institute

ORCID: 0000-0001-6783-8500
MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

4in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336
Top 100%
0DataRank
Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more

Papers

Driven by 11 papers — median percentile 0. Top paper: “Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer”.

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer

Nature Communications(2021)10.1038/s41467-021-25769-z
N/A
1.8DataRank · unranked
48 citations

Jennifer L. Guerriero, Romualdo Barroso‐Sousa, Tianyu Li, Tess A. O’Meara, Anita Giobbie‐Hurder +24 more

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2500
N/A
0.835DataRank · unranked
261 citations

Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot +17 more

Mechanical checkpoint regulates monocyte differentiation in fibrotic niches

Nature Materials(2022)10.1038/s41563-022-01293-3
N/A
0.672DataRank · unranked
87 citations

Anna E. Marneth, Kwasi Adu‐Berchie, Joshua M. Grolman, Christina M. Tringides, Yutong Liu +10 more

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Blood(2021)10.1182/blood.2021010867
N/A
0.564DataRank · unranked
42 citations

Yi Zhang, Alexandra Savell, Teddy Huang, Nicoletta Cieri, Emily M. Thrash +33 more

Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy

Nature Communications(2023)10.1038/s41467-023-37230-4
N/A
0.515DataRank · unranked
30 citations

Daniel DiToro, Joel Henderson, Sujal I. Shah, Mike Manos, Mariano Severgnini +6 more

Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab

OncoImmunology(2024)10.1080/2162402x.2024.2432723
N/A
0.292DataRank · unranked
6 citations

Giuseppe Tarantino, Mariano Severgnini, Joanna Bagińska, Anita Giobbie‐Hurder, Jason L. Weirather +14 more

A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation

Cancer Cell(2021)10.1016/j.ccell.2021.02.003
N/A
0DataRank · unranked
60 citations

Shanye Yin, Elisa Ten Hacken, Tomasz Sewastianik, Mohamed Uduman, Alba Font‐Tello +24 more

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336
Top 100%
0DataRank
Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more

Data from A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

(2023)10.1158/1078-0432.c.6531336.v1
Top 100%
0DataRank
Top 100%0 citations

Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao +29 more

Data from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6530168
Top 100%
0DataRank
Top 100%0 citations

Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot +17 more

Data from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6530168.v1
Top 100%
0DataRank
Top 100%0 citations

Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot +17 more